Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood

Journal of Immunotoxicology

Volumn 10, Issue 4, 2013, Pages 373-379

  Granum, Berit ^a   Haug, Line S ^a   Namork, Ellen ^a   Stølevik, Solvor B ^a   Thomsen, Cathrine ^a   Aaberge, Ingeborg S ^a   Van Loveren, Henk ^b,c   Løvik, Martinus ^a,d   Nygaard, Unni C ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Childhood; Immunotoxicity; Infections; Perfluoroalkyl substances; Pre natal exposure; Vaccination response

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN E ANTIBODY; MEASLES ANTIBODY; MEASLES VACCINE; ORGANOFLUORINE DERIVATIVE; PERFLEXANE; PERFLEXANE SULFONATE; PERFLUOROALKYL SUBSTANCE; PERFLUORONONANOIC ACID; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID; RUBELLA ANTIBODY; RUBELLA VACCINE; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ALLERGY; ANTIBODY TITER; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BIRTH WEIGHT; BLOOD SAMPLING; BREAST FEEDING; CHILD; CHILDHOOD DISEASE; COMMON COLD; DISEASE ASSOCIATION; ECZEMA; ELISA KIT; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; IMMUNOTOXICITY; INFANT; INFECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MATERNAL BLOOD; MATERNAL PLASMA; OTITIS MEDIA; OUTCOME ASSESSMENT; PREGNANT WOMAN; PRENATAL EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; TREATMENT RESPONSE; VACCINATION; WHEEZING;

ALKANESULFONIC ACIDS; ALKENES; ANTIBODIES, VIRAL; ASTHMA; CAPRYLATES; CHILD, PRESCHOOL; COHORT STUDIES; COMMON COLD; FEMALE; FLUOROCARBONS; FOLLOW-UP STUDIES; GASTROENTERITIS; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSION; INCIDENCE; MALE; NORWAY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VACCINES;

EID: 84879516558     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2012.755580     Document Type: Article

References (39)

1. 3M Company. 2000. Phase-out plan for PFOS-based products. St. Paul, MN: U.S. Environmental Protection Agency Public Docket AR226-0588 U.S. EPA.
2. Apelberg, B. J., Witter, F. R., Herbstman, J. B., et al. 2007. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ. Health Perspect. 115:1670-1676.
3. Brieger, A., Bienefeld, N., Hasan, R., et al. 2011. Impact of perfluorooctanesulfonate and perfluorooctanoic acid on human peripheral leukocytes. Toxicol. In Vitro 25:960-968.
4. C8 Project Panel Study. 2012. Probable link evaluation of infectious diseases. Available from: http://www.c8sciencepanel.org/prob-link.html [Last accessed 1 Oct 2012].
5. Corsini, E., Sangiovanni, E., Avogadro, A., et al. 2012. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 258:248-255.
6. DeWitt, J. C., Peden-Adams, M. M., Keller, J. M., and Germolec, D. R. 2012. Immunotoxicity of perfluorinated compounds: Recent developments. Toxicol. Pathol. 40:300-311.
7. Dong, G. H., Zhang, Y. H., Zheng, L., et al. 2009. Chronic effects of perfluorooctanesulfonate exposure on immunotoxicity in adult male C57BL/6 mice. Arch. Toxicol. 83:805-815.
8. European Union. 2006. Directive 2006/122/ECOF the European parliament and of the council of 12 December 2006 amending for the 30th time Council Directive 76/769/EEC on the approximation of the laws, regulations and administrative provisions of the Member States relating to restrictions on the marketing and use of certain dangerous substances and preparations (perfluorooctane sulfonates). Available form: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri= CELEX:32006L0122:en:NOT [Last accessed 22 Oct 2012].
9. Fei, C., McLaughlin, J. K., Lipworth, L., and Olsen, J. 2010. Prenatal exposure to PFOA and PFOS and risk of hospitalization for infectious diseases in early childhood. Environ. Res. 110:773-777.
10. Fromme, H., Tittlemier, S. A., Volkel, W., et al. 2009. Perfluorinated compounds: Exposure assessment for the general population in Western countries. Int. J. Hyg. Environ. Health 212:239-270.
11. Glynn, A., Berger, U., Bignert, A., et al. 2012. Perfluorinated alkyl acids in blood serum from primiparous women in Sweden: Serial sampling during pregnancy and nursing, and temporal trends 1996-2010. Environ. Sci. Technol. 46:9071-9079.
12. Grandjean, P., Andersen, E. W., Budtz-Jorgensen, E., et al. 2012. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 307:391-397.
13. 1 mice. J. Toxicol. Sci. 34:687-691.
14. Gutzkow, K. B., Haug, L. S., Thomsen, C., et al. 2012. Placental transfer of perfluorinated compounds is selective: A Norwegian Mother and Child sub-cohort study. Int. J. Hyg. Environ. Health 215:216-219.
15. Haug, L. S., Huber, S., Becher, G., and Thomsen, C. 2011. Characterisation of human exposure pathways to perfluorinated compounds: Comparing exposure estimates with biomarkers of exposure. Environ. Int. 37:687-693.
16. Haug, L. S., Salihovic, S., Jogsten, I. E., et al. 2010. Levels in food and beverages and daily intake of perfluorinated compounds in Norway. Chemosphere 80:1137-1143.
17. Haug, L. S., Thomsen, C., and Becher, G. 2009a. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. J. Chromatogr. A 1216:385-393.
18. Haug, L. S., Thomsen, C., and Becher, G. 2009b. Time trends and the influence of age and gender on serum concentrations of perfluorinated compounds in archived human samples. Environ. Sci. Technol. 43:2131-2136.
19. Holsapple, M. P., Paustenbach, D. J., Charnley, G., et al. 2004. Symposium summary: Children's health risk-what's so special about the developing immune system? Toxicol. Appl. Pharmacol. 199:61-70.
20. Houde, M., Martin, J. W., Letcher, R. J., et al. 2006. Biological monitoring of polyfluoroalkyl substances: A review. Environ. Sci. Technol. 40:3463-3473.
21. Kato, K., Wong, L. Y., Jia, L. T., et al. 2011. Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999-2008. Environ. Sci. Technol. 45:8037-8045.
22. 1 mice. Toxicol. Sci. 103:77-85.
23. Lau, C., Anitole, K., Hodes, C., et al. 2007. Perfluoroalkyl acids: A review of monitoring and toxicological findings. Toxicol. Sci. 99:366-394.
24. Luster, M. I., Johnson, V. J., Yucesoy, B., and Simeonova, P. P. 2005. Biomarkers to assess potential developmental immunotoxicity in children. Toxicol. Appl. Pharmacol. 206:229-236.
25. Magnus, P., Irgens, L. M., Haug, K., et al. 2006. Cohort profile: The Norwegian Mother and Child Cohort Study (MoBa). Int. J. Epidemiol. 35:1146-1150.
26. Nilsen, R. M., Vollset, S. E., Gjessing, H. K., et al. 2009. Self-selection and bias in a large prospective pregnancy cohort in Norway. Pediatr. Perinat. Epidemiol. 23:597-608.
27. Okada, E., Sasaki, S., Saijo, Y., et al. 2012. Prenatal exposure to perfluorinated chemicals and relationship with allergies and infectious diseases in infants. Environ. Res. 112:118-125.
28. Peden-Adams, M. M., Keller, J. M., Eudaly, J. G., et al. 2008. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 104:144-154.
29. Stockholm Convention on Persistent Organic Pollutants (POPs). 2009. Available form: http://chm.pops.int/Convention/Media/Publications/tabid/506/ language/en-US/Default.aspx [Last accessed 22 Oct 2012].
30. Stølevik, S. B., Nygaard, U. C., Namork, E., et al. 2011. Prenatal exposure to polychlorinated biphenyls and dioxins is associated with increased risk of wheeze and infections in infants. Food Chem. Toxicol. 49:1843-1848.
31. Stølevik, S. B., Nygaard, U. C., Namork, E., et al. 2013. Prenatal exposure to polychlorinated biphenyls and dioxins from the maternal diet may be associated with immunosuppressive effects that persist into early childhood. Food Chem. Toxicol. 51:165-172.
32. Thomsen, C., Haug, L. S., Stigum, H., et al. 2010. Changes in concentrations of perfluorinated compounds, polybrominated diphenyl ethers, and polychlorinated biphenyls in Norwegian breast-milk during twelve months of lactation. Environ. Sci. Technol. 44:9550-9556.
33. United States Environmental Protection Agency (US EPA). 2006. 2010/1015 PFOA Stewardship Program. Available form: http://www.epa. gov/oppt/pfoa/pubs/ stewardship [Last accessed 22 Oct 2012].
34. van Loveren, H., and Piersma, A. 2004. Immunotoxicological consequences of perinatal chemical exposures. Toxicol. Lett. 149:141-145.
35. van Loveren, H., van Amsterdam, J. G., Vandebriel, R. J., et al. 2001. Vaccine-induced antibody responses as parameters of influence of endogenous and environmental factors. Environ. Health Perspect. 109:757-764.
36. Vestergren, R., and Cousins, I. T. 2009. Tracking the pathways of human exposure to perfluorocarboxylates. Environ. Sci. Technol. 43:5565-5575.
37. Wang, I. J., Hsieh, W. S., Chen, C. Y., et al. 2011. The effect of prenatal perfluorinated chemicals exposures on pediatric atopy. Environ. Res. 111:785-791.
38. WHO. 2012. Guidance for Immunotoxicity Risk Assessment for Chemicals. Geneva: World Health Organization. IPCS harmonization project document; No. 10. ISBN 978 92 4150 330 3.
39. Zheng, L., Dong, G. H., Jin, Y. H., and He, Q. C. 2009. Immunotoxic changes associated with a 7-day oral exposure to perfluorooctanesulfonate (PFOS) in adult male C57BL/6 mice. Arch. Toxicol. 83:679-689.